Compare GDHG & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDHG | BMRA |
|---|---|---|
| Founded | 2008 | 1971 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.2M |
| IPO Year | 2023 | N/A |
| Metric | GDHG | BMRA |
|---|---|---|
| Price | $2.65 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.2K | ★ 19.0K |
| Earning Date | 07-11-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,666,899.00 | $4,884,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.40 | $2.08 |
| 52 Week High | $1,968.41 | $10.16 |
| Indicator | GDHG | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 26.54 | 40.96 |
| Support Level | $2.56 | $2.30 |
| Resistance Level | $3.08 | $2.67 |
| Average True Range (ATR) | 0.41 | 0.12 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 6.67 | 12.30 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.